



CC: analiasimonazzi@gmail.com, aliciagracielacid@gmail.com, alejandrojparedes@gmail.com,lschofs@vet.unicen.edu.ar, gonzo@unsa.edu.ar, sdpalma@fcq.unc.edu.ar
Subject: Therapeutic Delivery - Decision on Manuscript ID TDE-2018-0037.R3
Body: 26-Jul-2018 
  
Dear Dr. Bermúdez, 
  
It is a pleasure to accept your manuscript entitled "Development and in vitro evaluation of solid
dispersions as strategy to improve albendazole biopharmaceutical behavior" in its current form
for publication in Therapeutic Delivery. Our production department will be in touch with the
galley proofs - please do let me know if you are going to be away at any point and unable to
check them. 
 
Please note, we are able to offer a fast-track production service, for a fee of $800, providing
guaranteed online publication within 3 weeks (subject to turnaround of proofs by the author
within 3 working days). Should you be interested in this service, please let me know. 
  
Common errors to check and watch out for when approving your proofs (those that are harder
for our copy editors to catch): 
 – Have you listed all your co-authors, and spelt their names correctly? 
 – Have you included correct affiliation details for yourself and your co-authors? 
 – Have you included all your funding information, including grant numbers, in the
acknowledgement section (i.e., NIH, Wellcome Trust, etc.)? 
  
Although corrections can be made after publication, these will only be carried out if they are
deemed by the editor to be critical to the understanding of the article. So it is important to
check information such as the above is correct when the article goes to print, as it cannot
always be corrected at a later date. 
  
Please note that the version uploaded to the ScholarOne system is classified as the ‘Author’s
final version’. You are able to upload this version to your institutional repository if required. If
you would like us to send you a copy of the author’s final version, please let me know. For all
other uses of this article version, please refer to the journal’s self-archive policy. 
  
Therapeutic Delivery offers an open access option, whereby for a fee, articles can be made
freely available for all to read. As of 2016, the journal saw over 10-times more readers for
articles that were freely available, showing a distinct advantage for the open access option.
Pricing varies by article type; for peer-reviewed content (i.e., Original Research or Review
articles), the fee is $2,500; for content not reviewed externally (i.e., Editorials or
Commentaries), the fee is $850. For more information, visit our website here:
https://www.future-science-group.com/services/for-researchers/open-access/. If you are
interested in taking this option, please let me know. 
  
In addition, Colour Printing can enhance the impact of your article's figures with readers. Should
you wish your figures to appear in colour in the print issue of the journal, there is a fee of $220
for the first figure and $135 for each subsequent figure. Please note that charges for colour
figures only apply for print issues of the journal; all figures appear online in colour at no cost. If
you are interested in having one or more of your figures printed in colour, please let me know. 
  
Finally, if your institution does not already subscribe to Therapeutic Delivery, it would be great if
you would be willing to email your librarian to recommend the journal to them (or alternatively,
reply to this email if this is of interest, and we can contact your librarian to discuss free trial and
subscription options). 
  
Thank you for your contribution.  On behalf of the Editors of Therapeutic Delivery, we look
forward to working with you in the future. 
  
Sincerely, 
 Rhiannon Finnie 













Development and in vitro evaluation of solid dispersions as 




Journal: Therapeutic Delivery 
Manuscript ID TDE-2018-0037.R3 
Manuscript Type: Preliminary Communication 









Aim: Solid dispersions using Poloxamer 407 as carrier were developed to improve 
albendazole solubility and dissolution profiles. Methodology: Albendazole/Poloxamer solid 
dispersions were prepared, and dissolution profiles were mathematically modeled and 
compared with physical mixtures, pharmaceutical albendazole, and a commercial formulation. 
Results: Poloxamer 407 increased exponentially albendazole solubility, in about 400% when 
95% w/w of polymer compared with its absence. Solid dispersions initial dissolution rate was 
3 to 20-fold higher than physical mixtures, the drug and the commercial formulation. All the 
solid dispersions required less than 2.2 min to reach an 80% of albendazole dissolution, while 
the commercial formulation needed around 40 min. Conclusion: Solid dispersions improved 
albendazole solubility and dissolution rate, what could result in a faster absorption and an 
increased bioavailability. 
 
Keywords: Solid dispersions; Poloxamer; Albendazole; Solubility; Initial dissolution 
rate; Dissolution efficiency; Lumped model. 


































































It has been well proven that solubility and gastrointestinal permeability play a crucial 
role in controlling rate and extent of drug absorption, and therefore, in vitro drug product 
dissolution can be correlated with in vivo bioavailability [1]. A fundamental property for drug 
absorption after oral administration is its aqueous solubility. Evidence suggests that a drug 
molecule must be enough soluble in water to be easily administered to the cell membrane, but 
it must be also enough hydrophobic to pass through it [2].  
For this reason, while a drug with poor aqueous solubility will exhibit a limited 
dissolution rate, a drug with poor membrane permeability will exhibit a limited permeation 
rate. This has been one of the most critical issues in pharmaceutical research field for many 
decades. 
Literature has emphasized the increased number of insoluble drugs that are candidates to 
be formulated in a dosage form [3, 4]. Consequently, pharmaceutical research area that focus 
on enhancing the oral bioavailability of active agents aims to improve the solubility of poorly 
water soluble drugs, to enhance their dissolution rate and absorption kinetics. Moreover, these 
drugs offer limited administration routes due to their few formulation alternatives [5]. 
Albendazole (ABZ) is widely used in both veterinary and human medicine for the 
treatment of parasitic infections causing intestinal disorders [6, 7]. ABZ has low aqueous 
solubility and high permeability, and therefore, it is not well absorbed in the gastrointestinal 
tract. As a consequence, it is classified as a Class II drug by the Biopharmaceutics 
Classification System [1], having a low dissolution rate [8, 9].  
Currently ABZ is available as tablets or suspensions with high doses of active agent and 
its therapeutic efficacy is compromised due to its low aqueous solubility [10]. To overcome 
these drawbacks, it is important to increase the aqueous solubility and therefore the 

































































dissolution rate of ABZ. In this context, the challenge for this broad-spectrum drug lies in the 
development of new formulations. Following this guideline, different strategies have been 
developed to improve ABZ bioavailability, such as formulation of solid dispersions [11-14], 
complexation with cyclodextrin [15, 16], co-grinding [5], the synthesis of new analogs with 
higher solubility [17, 18], microcrystals [19], nanocrystals [20], and more recently, several 
nano-particulate formulations [21-24]. However, the need of reproducible, inexpensive, 
scalable and organic solvent-free approaches to carry ABZ still remains a challenge. 
Solid dispersions (SDs) are considered one of the most successful strategies to improve 
the dissolution profile of poorly soluble drugs. In 1971, Chiou and Riegelman defined SDs as 
dispersions of one or more active ingredients in inert carriers or matrixes at solid state 
prepared by melting (fusion), solvent, or melting-solvent procedures [25]. SDs can be 
classified into four generations according to the physical state of the carrier [26, 27]. First 
generation SDs are crystalline and consist of a crystalline drug dispersed in a crystalline 
carrier forming an eutectic or monotectic mixture [28-31]. The second generation of SDs 
includes amorphous carriers which are mostly polymers, such as crospovidone [32] and 
hydroxypropylmethylcellulose [33], among others. In the third generation of SDs, surface 
active agents or self-emulsifier are incorporated as carriers or additives and help to improve 
problems such as precipitation. The addition of surfactants and emulsifiers in SDs improves 
not only the dissolution profile, but also the physical and chemical drug stability. Finally, the 
fourth generation of SDs consists of a controlled release solid dispersion containing poorly 
water-soluble drugs with a short biological half-life [34]. 
In SDs the polymer serves as a carrier in which the drug is dispersed. Therefore, polymer 
selection is very important since it influences manufacturing, bioavailability, and stability of 
the SDs. Initial assessment of potentially “useful” excipients should be based on basic 

































































physicochemical properties of the polymers, such as glass transition temperature (Tg), 
hygroscopicity, and solubilization capacity, among others. Several carriers were evaluated for 
ABZ SDs, such as polyvinylpyrrolidone [11, 35], polyethylene glycol [14, 36], Gelucire [36], 
and Poloxamer 188 [12].  
Poloxamers, a family of triblock copolymers of ethylene oxide and propylene oxide, are 
nonionic surfactants with solubilizing properties. They are marketed under a variety of trade 
names, such as Pluronic™ from BASF. Poloxamers are available in different ethoxylated 
content and molecular weight. Their polymeric nature makes them suitable for most of the 
standard procedures used to prepare SDs. Moreover, they present an improved miscibility 
with many pharmaceutical actives due to their structure in comparison with nonpolymeric 
surfactants. In particular, Poloxamer 407 (P 407) is accepted by FDA as an "inactive" 
ingredient for different types of preparations (e.g., IV, inhalation, oral solution, suspension, 
ophthalmic or topical formulations) [37].  
The aim of this work was to prepare, characterize and in vitro evaluate ABZ SDs, 
prepared by the fusion method, based on P 407 for enhancing the solubility and dissolution 
rate of the drug, pursuing the improvement of its absorption rate, and then its bioavailability. 
In this context, solubility studies and dissolution test were performed to compare the SDs 
behavior with other ABZ formulations. The obtained data were fitted using a mathematical 
model developed and validated by our research group, which allowed to calculate several 
parameters of pharmaceutical relevance. An analysis based on the independent method was 
also performed to compare the dissolution profile of SDs with different ABZ/P 407 
proportions. 
 
Materials and methods  

































































Materials   
ABZ of pharmaceutical grade was purchased from Todo Droga (Córdoba, Argentina) and 
Poloxamer 407 from BASF® (Germany).   
The commercial formulation of ABZ (CF) was Vermizole
®
 (Lafedar Laboratory, 
Argentina). Each tablets contains 200 mg of ABZ and the following excipients: magnesium 
stearate (2 mg), sodium lauryl sulfate (8 mg), croscarmellose sodium (32 mg), lactose SD 
(enough quantity for 400 mg), sodium glycolate starch (18 mg), pregelatinized starch (51 mg), 
and hydroxypropylmethylcellulose (4 mg) [101]. Apparently, according to the reported 
excipients used in the preparation of the tablet, this formulation is prepared by direct 
compression.  
ABZ does not present enantiomers, although albendazole sulphoxide, its active 
metabolite does due to the presence of a chiral sulfur atom [6, 38]. 
ABZ Ttablets containing 200 mg of the drug per unit were pulverized and sieved. The 
210-µm size fraction was used for dissolution tests. The powder was stored in a screw-cap 
vial until use. 
All other reagents were of analytical grade. 
 
SDs preparation.   
    Four SDs using P 407 as carrier with 5, 10, 25 and 50 % w/w of ABZ (SD1, SD2, SD3 
and SD4, respectively) were prepared by the fusion method. Briefly, the drug was 
homogeneously dispersed by stirring in the molten carrier at 63 °C. The resulting 
homogeneous preparation was rapidly cooled in liquid nitrogen and then pulverized. The 
210-µm particle size fraction was obtained by sieving and kept in a screw-capped glass vial 
until use. Physical mixtures (PMs) were prepared by mixing the components in the same 
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proportions in a Laboratory-scale V-blender for 5 min (5, 10, 25 and 50 % w/w of ABZ, 
named PM1, PM2, PM3 and PM4, respectively), using the 210-µm particle size fractions of 
sieved ABZ and P 407. The powders were stored in a screw-cap vial until use. 
 
Physico-chemical characterization of the materials.  
X-ray diffraction (XRD) and Fourier Transform Infrared (FTIR) spectroscopy. 
 Pharmaceutical grade ABZ, P 407, SD4, and PM4 were analyzed by X-ray diffraction 
using a DRX Philips PW1800 diffractomer. Assays were performed at 40 KV and 30 mA in a 
range of 5-70 ° 2Theta at a rate of 0.02 ° 2Theta / s.  
These samples were also characterized by FTIR spectroscopy using a Spectrum GX-Perkin 
Elmer Spectrometer over the region 4000-400 cm
-1
, after mixing them with potassium 
bromide (spectroscopic grade) and compressing into disks using a hydraulic press. 
 
Scanning Electron Microscopy (SEM) 
   The morphology of pharmaceutical grade ABZ, P 407, SD3, SD4, PM3, and PM4 was 
evaluated by SEM. Samples were gold covered (Denton Vacuum metallizer, LLC, Desk-IV) 
and observed by a Scanning electron microscope (JEOL JSM-6480LV, Japan). 
 
Differential Scanning Calorimetry (DSC) 
 Pharmaceutical grade ABZ, P 407, SD4, and PM4 DSC thermograms were obtained using 
a Q200 (TA instrument). Samples were accurately weighed into hermetic aluminum pans, 
then hermetically sealed with aluminum lids and heated from 25°C to 250°C at a heating rate 
of 10°C/min under constant purging of dry nitrogen 20 ml/min. An empty hermetic aluminum 
pan, sealed in the same way as the sample, was used as reference. 


































































Phase solubility studies 
 An excess of ABZ was added to 5 ml of a 0.1 N HCl containing increasing concentrations 
of P 407 (1, 3, 5, 10 and 15 % w/v) in sealed glass vials. Then they were placed in a bath 
under stirring at room temperature for 96 hours to reach solubility equilibrium. After that, 
suspensions were filtered through a 0.45 µm mixed cellulose ester membrane, and the filtrate 
was assayed for ABZ concentration spectrophotometrically at λ=302 nm, using the 
corresponding calibration curve constructed with standard solutions of ABZ in 0.1 N HCl.  
 
Saturation solubility studies 
 For saturation solubility studies, an excess amount of pharmaceutical grade ABZ, SDs 
and PMs was added into sealed glass vials with 10 ml of 0.1 N HCl. They were maintained in 
a water bath under stirring at 37 °C for 4 days. After that, the samples were filtered through a 
0.45 µm mixed cellulose ester membrane, and the filtrate was analyzed 
spectrophotometrically to determine ABZ concentration.  
 
Biopharmaceutical characterization 
 Dissolution tests of SDs, PMs, pharmaceutical grade ABZ and CF were performed using 
an USPXXIV dissolution apparatus 2 (SOTAX AT 7 smart) at 37±0.5°C and under stirring at 
50 rpm. The necessary amount of powdered samples having 50 mg of ABZ was weighed 
accurately and added into 900 ml of filtered and degassed 0.1 N HCl used as dissolution 
medium. At predetermined intervals of time four-milliliter of filtered aliquots were withdrawn 
and replaced by fresh medium to keep the volume constant. The concentration of dissolved 
drug was determined spectrophotometrycally.  

































































Dissolution data were analyzed by a lumped second-order kinetic model developed [39] and 
validated [40] by our research group. To compare the different dissolution profiles, initial 
dissolution rate (IDR), sampling time (ttmin), dissolution time (tX%), dissolution efficiency (DE), 
similarity and difference factors (f1 and f2, respectively) and mean dissolution time (MDT) 
were calculated, according to the independent statistical analysis methods [41]. 
 
Data analysis 
 Solubility and dissolution assays were performed by triplicate and data are presented as 
the mean ± the standard deviation (s). Statistical analysis was performed using Polymath 6.0 
software. For statistical comparisons, a p-value less than 0.05 (p < 0.05) was considered 
significant.  
 
Results and discussion 
Physico-chemical characterization of the materials 
X-ray diffraction and IR spectroscopy  
SD4 and PM4 were selected to perform characterization studies because ABZ was in 
major proportion in them and so, any change or interaction would be easier detected. 
Samples of pharmaceutical grade ABZ, P 407, SD4 and PM4 were analyzed by XRD in 
order to evaluate their crystalline state. As shown in Fig. 1, the diffraction profile of ABZ 
evidenced its crystalline nature, showing numerous diffraction peaks at 6.80°, 11.30°, 13.8°, 
17.9°, 19.5°, 20.8°, 22.1°, 24.43°, 24.6°, 27.2°, 28.4° and 29.9°, in concordance with the 
reported by other authors [13, 42]. In XRD diffractogram, the characteristic peaks of P 407 
were observed at 19.2° and 23.2°, as reported in literature [43]. (Fig. 1). 
In both PM4 and SD4, the XRD patterns showed no changes in the signals assigned to 

































































the drug and the polymer, indicating no interactions. However, it was observed that some of 
the characteristic peaks of ABZ were reduced or even absent in SD4, which could be 
suggesting a slightly reduction in crystallinity when compared to PM4. This could lead to an 
improvement in solubility because amorphous forms are more easily solubilized than the 
crystalline forms. 
FTIR spectra of ABZ, P 407, PM4 and SD4 (Fig. 2) were compared to evaluate possible 
interactions between the drug and the polymer or changes in the wavelength of the functional 
groups of the drug. 
ABZ is a N-aryl secondary urethane, that exhibits a medium intensity peak at 3322 cm
-1
 
attributed to N-H stretching [44]. The band due to the carbonyl stretching vibration, termed as 
amide I band of urethanes, occurs in the region of 1740-1680 cm
-1
. In view of these, the band 
present at 1711 cm
-1
 was assigned to the amide I vibration of the carbamate group [44]. 
Urethanes also exhibit amide III band just like amides, but in the region of 1260-1220 cm
-1
. In 
this line, the very strong band present at 1271 cm
-1
 was due to the combination of N-H 
deformation and C-N stretching vibration motion. In the ABZ FTIR spectrum the signals 
corresponding to aromatic ring stretching occurred at 1630 cm
-1
. The P 407 FTIR spectrum 
showed the principal absorption bands at 1343 cm
-1
 and 1110 cm
-1
 corresponding to in-plane 
O-H bend and C-O stretching, respectively, coinciding with the reported for P 407 [45]. All 
signals recently explained remained practically unaltered for SD4 and PM4 at the same wave 
numbers. In both preparations, the peaks corresponding to each component were observed and 
no new peaks appeared. For this reason, it could be concluded that there were no chemical 
interactions among ABZ and P 407 as consequence of their close contact in both the SD and 
PM or during their manufacturing process.  
 

































































Scanning Electron Microscopy (SEM) 
 Pharmaceutical grade ABZ, P 407, SD3, SD4, PM3 and PM4 were characterized by SEM 
in order to determine the morphology of the drug within the polymeric matrix. SEM images 
presented ABZ as small particles of irregular shape and rough surface (Fig. 3a). P 407 was 
observed as large spheres of smooth surface and irregular shape of different sizes (Fig. 3b). 
Figures 3c and 3d showed that SD3 and SD4 presented rough surface particles of different 
sizes, where the spherical particles of P 407 and irregular particles of ABZ could not be 
distinguished. In Figures 3e and 3f, corresponding to PM3 and PM4, respectively, ABZ was 
distributed on the surface of P 407 maintaining its structure.  
 
Differential Scanning Calorimetry 
 DSC analysis of pharmaceutical grade ABZ, P 407, SD4 and PM4 (Fig. 4) was carried 
out to determine the thermal behavior of the samples and the formation of amorphous SDs, 
which would be indicated by the attenuation or disappearing of the drug melting peak in the 
thermogram. 
ABZ and P 407 presented an endothermic peak at 214.54°C and 53.28°C, respectively, 
corresponding to their reported melting points [7]. However, an overlap of two peaks was 
observed in the ABZ run, probably because no recrystallization process of the drug was 
carried out. This behavior was also reported by other authors [46]. Regarding the binary 
mixtures, it could be detected that the endothermic peak of the drug was attenuated in the PM, 
whereas it almost disappeared in the SD, probably because ABZ got dissolved in the molten 
carrier throughout the test. The peak corresponding to the melting temperature of the carrier 
did not undergo a major change neither in the PM nor in the SD, revealing an ordered state of 
P407 in both preparations. However, the SD4 plot showed the peak corresponding to P 407 as 

































































a broad diffuse and displaced endotherm, what would be indicating the formation of a eutectic 
mixture between the two components (drug and polymer) during the assay.  
 
Phase solubility studies 
 As previously mentioned, P 407 has surfactant properties with a critical micelle 
concentration (CMC) of 2.8 µM [47]. Thus, an increase in ABZ solubility caused by this 
polymer would be expected. 
Results indicated that the solubility of ABZ increased linearly (from 0.23 to 0.91 mg/ml) 
along with the concentrations of the surfactant polymer in the solution from 0% to 15% (w/v), 
following a linear equation with a slope of 0.042±0.005 and an intercept of 0.32±0.04 (R
2
 = 
0.945). This result is similar to that reported by Torrado et al. [11]. 
This could be because at very low concentrations, the P 407 only exists as individual 
strings, but as the concentration of P 407 increases reaching the CMC, the polymer chains 
start to associate to form micelles, thus the hydrophobic part of the copolymer avoid contact 
with the aqueous medium in which it is diluted [48]. These micelles have hydrophobic core of 
PO chain and hydrophilic shell formed by EO chains. The hydrophobic PO core can 
incorporate water insoluble molecules, promoting faster and more complete solubility [47]. 
The increase in the solubility of ABZ could be also explained by the decrease in the 
interfacial tension between the drug and the medium of the solution provoked by the P 407 
[49]. 
 
Saturation solubility studies 
 The saturation solubility of ABZ as a function of P 407 proportion followed a unique 
curve (standard deviation below 6%), regardless of the type of binary mixture (SD or PM). 

































































The saturation solubility showed an exponential growth when polymer concentration 
increased. Polymer at 95 %w/w caused an increase in ABZ solubility of about 4-fold with 
respect to solubility in the absence thereof. However, for Poloxamer proportions lower than 
50% in the mixtures, the saturation solubility reached a plateau with a value two times higher 
than that corresponding to ABZ (0.398 mg/ml).  
 The data were modeled using Equation 1 with a correlation index of R
2
 = 0.9842 (Fig. 5). 
 = 0.821 + 6.43 − 08 × exp0.168 × %    (Eq. 1) 
Where SS is the ABZ saturation solubility in mg/ml and P% is the Poloxamer percentage 




 Increasing the dissolution rate of a drug may result in an improvement in its absorption 
kinetic, leading probably to an enhancement in its bioavailability. This could result in a 
reduction in the dose needed to reach the therapeutic effect, which is relevant since ABZ is 
poorly absorbed from the gastrointestinal tract at the usual therapeutic doses, and adverse 
effects have generally been restricted to gastrointestinal disturbances associated more 
frequently with high doses. Therefore, grater ABZ solubility and absorption rate would 
probably help in reducing the therapeutic doses, avoiding adverse effects. 
In this context, dissolution profiles of the different SDs in 0.1 N HCl were studied and 
compared with the PMs, the CF and pharmaceutical grade ABZ (Fig. 6). 
  
 The experimental data of the cumulative amount of dissolved ABZ profiles were well 
correlated by a model previously developed and validated by our research group [39, 40]. 

































































This simple model can lump together both diffusional and polymer relaxation steps present in 
this process, and it is represented by Equation 2 [40]: 
% =	 ××	 	 	 	 	 	 	 	 	 	 (Eq. 2 [40]) 
  Where M% is the percentage of drug dissolved at time t, and parameters a and b are 




), respectively. Table 1 shows the values of the parameters a and 
b and the corresponding correlation coefficient for SDs, PMs, ABZ and CF. 
 Interestingly, the value of the parameter a is the IDR [40], since the dissolution rate at any 




∗            (Eq. 3 [40]) 
And therefore, when t = 0, the IDR is: 
!"# = % $%&	 = 		'        (Eq. 4) 
Significant differences in the IDR were observed between SD and CF, ABZ and PM 
samples (3 to 20-fold). Although the values of the saturation solubility were similar when the 
same P 407 proportion for both SDs and PMs, the IDR were remarkably different. While all 
the SDs presented values greater than 60 % min
-1
, neither of the PMs reached 25 % min
-1
. On 
the other hand, the CF IDR was almost 10-fold lower than the SDs.  
The model allowed calculating another interesting parameters of pharmaceutical 
relevance, which are also shown in Table 1. While tXmin corresponds to the percentage amount 
of drug dissolved at a given time, tX% is the time needed to dissolve a certain percentage 
amount of drug (Eq. 5). For example, t80% is the time needed to reach an 80% of dissolved 
drug, and this value can be used as an acceptance limit according to Pharmacopeias [41], 

































































considering it an immediate drug delivery if lower than 45 min. 
()% =	 )%*×)%	 	 	 	 	 	 	 	 	 	  (Eq. 5 [41]) 
On the other hand, DE is defined as the ratio between the area under the profile curve up 
to a certain final time tF and the area of the rectangle corresponding to 100% dissolved at 
the same time [41]. The importance of DE lies in considering both the dissolved amount 
and the dissolution rate. Using our model, DE for a final time tF, is given by: 





&&×-    (Eq. 6 [41]) 
Although IDR of pharmaceutical grade ABZ was greater than or equal to PM3, PM4 and 
CF, it has to be also taken into account the percentage amount dissolved at different times (ttmin). 
When the cumulative amount of ABZ dissolved from this sample reached near 9%, the 
dissolution almost stopped, at least for the tested 60 minutes. Besides the differences found in 
the IDR between SD and PM samples previously mentioned, significant differences in the t30min 
(between 20% and 40% approximately) were observed. Regarding to the t80%, all the SDs 
presented values lower than 2.2 min, meaning that the behavior corresponded to an immediate 
delivery. Only PM1 reached an 80% of drug dissolution during the evaluated period of time, 
while the CF t80% was just under the acceptance limit. The DE values were higher for all the SDs 
than for the corresponding PMs, CF and ABZ of pharmaceutical grade, showing clearly that 
these products are the best option due to both their high dissolution rate and percentage of ABZ 
dissolved. 
Differences in the dissolution profiles may be explained by the manufacture process of 
the SD, which impacts in their solid state properties. In the SD, the drug is already present in the 
molecular state as a “solid solution,” and thus the step of drug dissolution is bypassed. 

































































When the drug is part of the SD, its dissolution may be carrier mediated. Initially, a 
polymer-rich diffusion layer is formed between the solid dispersion and the dissolution medium. 
After diffusion of ABZ into the polymer-rich phase, the drug is further released into the 
dissolution medium [50]. 
To compare the dissolution profiles between the SDs with different ABZ/P 407 
proportions, independent statistical analysis methods were chosen. These methods include ratio 
tests and pair-wise procedures [41]. The pair-wise procedures include the difference and 
similarity factors (f1 and f2, respectively) [51-53]. The first one describes the error between two 
dissolution curves over all time points, and is defined as: 
5 =	∑ |89*	:9|
;<
∑ 89;< × 100        (Eq. 7 [51]) 
Where Ri and Di are the percent dissolved of the reference and the test sample at each 
time point i, and n is the number of experimental samples. This percent error is equal to zero 
when the test and drug reference profiles are identical. 
On the other hand, f2 is defined as the logarithmic transformation of the sum-squared 
error of differences between the test and the reference product over all time points: 
5= 	= 50	 × 	?@A BC1 + DEF	∑ #G − "G=	E H
*&.I × 	100	J  (Eq. 8 [51]) 
 The “Center for Drug Evaluation and Research” (Food and Drug Administration, USA) 
and the “Human Medicine Evaluation Unit of the European Agency for the Evaluation of 
Medicinal Products” have established as a criterion to consider similar two dissolution 
profiles, values of f1 lower than 15 (0 - 15) and f2 higher than 50 (50 – 100).  
 Since no significant differences were observed between the SDs dissolution profiles, all 
the data were fitted together using a unique curve, which model parameters a and b were 70.4 % 

































































min-1 and 0.7 min-1, respectively. To compare the dissolutions profiles between the different 
SDs, f1 and f2 were calculated using the unique curve profile as reference. Values of f1 and f2 
were 0.9 and 95.0 for SD1, 1.8 and 85.9 for SD2, 1.6 and 87.3 for SD3, and 2.7 and 80.6 for 
SD4, respectively. These results suggest that the profiles of the different SDs prepared in this 
work were similar. This is important from a practical point of view when developing a 
formulation, since a tablet with an adequate amount of drug and an acceptable final weight 
could be designed. 
Independent statistical analysis methods also include ratio tests that are relations between 
parameters obtained from the release assays of different formulations. Among these 
parameters, the MDT value is one of the most frequently used (Eq. 9), and it was calculated 
for the SDs to confirm the previously found from the analysis of f1 and f2. 
"K)%	 = 	∑ LM×	∆%
;LO<
∑ ∆%;LO<
        (Eq. 9 [41]) 
Where tjm = (tj + tj-1)/2 is the midpoint time between two samples and ∆M% is the 
additional amount of drug release between tj and tj-1. However, as we pointed out previously, 
since our model fitted very well the experimental data, MDTX% can be calculated as: 
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%R%         (Eq. 11) 
Finally: 
"K)% 	= 	  		
STE×R%	*		 0×,R%U<Q0×,R%VW
%      (Eq. 12) 

































































M% (tX%) is the percent of drug accumulated at t = tX%, and the value of tX is obtained 
from Equation 5. The values of MDT80% were 6.7, 6.0, 7.3 and 8.2 min for SD1, SD2, SD3 
and SD4, respectively, and 6.9 min for the unique curve that fitted all the data. There were no 
statically significant differences between them, confirming the similarity in the dissolution 
profiles of the SDs. 
Finally, ABZ initial intrinsic dissolution rate (IIDR) was calculated as a function of the 
ABZ content for the SDs (Eq. 13), and PMs (Eq. 14), and compared with ABZ of 
pharmaceutical grade (Fig. 7). 
!!"#X:	 YZ[T.[GE = 	−0.036 × \]^%+ 40.38    (Eq. 13) 
!!"#_	 YZ[T.[GE = 15.9	 × 	exp	−0.045 × \]^%   (Eq. 14) 
The IIDR was almost independent in the 5% to 50% w/w drug concentration range for the 
SDs. The IIDR was enhanced for the SDs compared with the ABZ of pharmaceutical grade. 
The mechanism by which the drug is dissolved probably begins with the formation of a 
polymer-rich diffusion layer between the SD and the dissolution medium. After diffusion into 
this polymer-rich phase, the drug reaches the dissolution medium either as solvated molecules 
or as amorphous particles at a rate controlled by the carrier. 
On the other hand, the IIDR for PMs was strongly influenced by the ABZ dissolution rate 
(drug controlled dissolution). The data were fitted adequately by an exponential equation (Eq. 
14). 
Finally, it is important to emphasize that in vitro solubility and dissolution studies 
represent an important link between the formulation design and its bioperformance. This is 
especially true for supersaturating formulations such as the SDs developed and evaluated in 

































































this work. However, to stablish an in vitro-in vivo correlation (IVIVC), an in vivo parameter is 
needed, to relate it to the in vitro parameters. The replacement of in vivo testing with in vitro 
approaches presupposes well-based understanding of the scaling factors associating the in 
vitro with the in vivo measurements. 
 
Conclusion 
The results obtained revealed that the use of P 407 as carrier in ABZ SDs markedly 
improved its solubility and dissolution rate compared with pharmaceutical grade ABZ and a 
commercial formulation. The polymer maintained a desirable level of a supersaturation state 
in the dissolution medium by preventing solvent-mediated crystallization over the time period 
needed for the absorption process. However, SDs showed a better behavior than the PMs with 
the same P 407 proportion, observed in their higher initial dissolution rate and sampling time 
values, and lower dissolution times. 
These approaches make SDs a very promising alternative strategy because the 
improvement of these properties could result in a faster absorption rate, and thus, in increased 
bioavailability of poorly water-soluble compounds as ABZ. However, further studies are 
required to advance in the development of these formulations considering the inherent 
thermodynamic instability associated to SDs, which could lead to relaxation, nucleation, and 
crystallization during storage. Undoubtedly, understanding the limits of the SDs and 
considering them when developing the drug delivery systems will be a key decision for the 
successful application of these materials. Moreover, further in vivo studies are necessary to 
evaluate the pharmacokinetic parameters of the SDs. 
 
Future Perspective 

































































It is expected that in the coming years there will be a considerable growth in the field of 
applications of solid dispersion to solve solubility-related challenges in pharmaceutical 
product development. This growth will be primarily driven by three factors: a) development 
and expansion of acceptable excipients, especially at the higher proportions needed for solid 
dispersions, b) application of newer technologies in the solid dispersions manufacture, and c) 
enhanced understanding of systems based on solid dispersions using predictive analytical 
tools to evaluated their stability and dissolution. 
 
Executive summary 
Physico-chemical characterization of Albendazole/Poloxamer solid dispersions 
• Four solid dispersions with different albendazole/Poloxamer proportion were prepared 
and characterized, showing no chemical interaction between the two components. 
• Albendazole phase solubility increased linearly (from 0.23 to 0.91 mg/ml) along with 
the Poloxamer concentrations in the solution from 0% to 15% (w/v). 
• Polymer at 95 %w/w caused an increase in ABZ saturation solubility of about 4-fold 
with respect to solubility in the absence thereof. 
Biopharmaceutical characterization 
• Dissolution profiles were adjusted correctly with a mathematical model developed and 
validated by our research group, which allowed calculating pharmaceutical relevant 
parameters. 
• Initial dissolution rate was 3 to 20-fold higher for solid dispersions than physical 
mixtures, pharmaceutical grade albendazole and a commercial formulation. 
• The time needed to reach an 80% of dissolved drug was lower than 2.2 min for all the 
solid dispersions, indicating a fast dissolution. 

































































• All solid dispersions presented higher dissolution efficiency than the other 
preparations. 
• Based on the independent statistical analysis methods, difference and similarity factors 
indicated no significant differences between solid dispersions dissolution profiles. 
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Figure 1. XRD diffractograms of pharmaceutical grade ABZ, P 407, SD4 and PM4.   
Figure 2. FTIR spectra of pharmaceutical grade ABZ, P 407, SD4 and PM4.  
Figure 3. SEM images: a) pharmaceutical grade ABZ; b) P 407; c) SD3; d) SD4; e) 
PM3 and f) PM4.   
Figure 4. DSC thermograms of pharmaceutical grade ABZ, P 407, SD4 and PM4.  
Figure 5. ABZ saturation solubility in HCl 0.1 N in presence of increasing P 407 
proportions. 
Bar errors cannot be distinguished since they are smaller than the symbols used for 
experimental data average.  
Figure 6. Dissolution profiles of ABZ in 0.1 N HCl.  
Figure 7. ABZ initial intrinsic dissolution rate (IIDR).   
 
Table Legends 
Table 1. Parameters of the Lumped model, sampling times, dissolution time for 80% 
and dissolution efficiency for SDs, PMs, pharmaceutical grade ABZ and CF. 
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Figure 1. XRD diffractograms of pharmaceutical grade ABZ, P 407, SD4 and PM4.    
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Figure 2. FTIR spectra of pharmaceutical grade ABZ, P 407, SD4 and PM4.  
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Figure 4. DSC thermograms of pharmaceutical grade ABZ, P 407, SD4 and PM4.  
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Figure 5. ABZ saturation solubility in HCl 0.1 N in presence of increasing P 407 proportions.  
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Figure 7. ABZ initial intrinsic dissolution rate (IIDR).    
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Table 1 Parameters of the Lumped model, sampling times, dissolution time for 80% and 

















5 10 15 30 60 
SD1  69.155 0.714 0.998 75.6 84.9 88.6 92.5 94.6 1.56 88.3 
SD2  80.616 0.839 0.997 77.5 85.8 89.0 92.4 94.1 1.37 88.5 
SD3  60.127 0.615 0.997 73.8 84.1 88.2 92.7 95.2 2.11 88.1 
SD4  71.622 0.774 0.977 73.5 82.0 85.2 88.7 90.6 1.69 84.9 
PM1 23.640 0.275 0.996 49.7 63.0 69.1 76.6 81.0 49.66 70.9 
PM2 20.604 0.246 0.992 46.1 59.4 65.7 73.6 78.2 NR* 67.9 
PM3 6.722 0.077 0.987 24.2 37.8 46.5 60.4 71.1 NR* 54.2 
PM4 3.341 0.050 0.978 13.4 22.3 28.6 40.0 50.0 NR* 35.9 
ABZ  19.640 2.140 0.904 8.4 8.8 8.9 9.0 9.1 NR* 8.8 
CF 6.744 0.059 0.983 26.0 42.3 53.5 72.7 84.5 40.31 65.1 
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